A phase I/II study of TAK-788 demonstrated an ORR of 54% in previously treated NSCLC patients harboring EGFR exon 20 insertions [45] and was granted a breakthrough therapy designation by FDA. This evidence concerns the gene EGFR and non-small cell lung carcinoma.